Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBIT Margin: 2020-2025

Historic EBIT Margin for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to 9.05%.

  • Xeris Biopharma Holdings' EBIT Margin rose 3281.00% to 9.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.68%, marking a year-over-year increase of 2779.00%. This contributed to the annual value of -16.57% for FY2024, which is 1028.00% up from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' EBIT Margin is 9.05%, which was up 44.44% from 6.27% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EBIT Margin registered a high of 9.05% during Q3 2025, and its lowest value of -289.55% during Q2 2021.
  • Over the past 3 years, Xeris Biopharma Holdings' median EBIT Margin value was -17.03% (recorded in 2024), while the average stood at -16.11%.
  • Per our database at Business Quant, Xeris Biopharma Holdings' EBIT Margin crashed by 7,408bps in 2021 and then surged by 21,480bps in 2022.
  • Xeris Biopharma Holdings' EBIT Margin (Quarterly) stood at -225.26% in 2021, then surged by 17,949bps to -45.77% in 2022, then spiked by 2,360bps to -22.17% in 2023, then skyrocketed by 2,496bps to 2.79% in 2024, then surged by 3,281bps to 9.05% in 2025.
  • Its last three reported values are 9.05% in Q3 2025, 6.27% for Q2 2025, and -5.14% during Q1 2025.